Stage IV Esophageal Cancer Clinical Trial
Official title:
A Phase II Study of Arsenic Trioxide (NSC 706363) in Patients With Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
This phase II trial is studying how well arsenic trioxide works in treating patients with metastatic or unresectable cancer of the esophagus or gastroesophageal junction. Drugs used in chemotherapy such as arsenic trioxide use different ways to stop tumor cells from dividing so they stop growing or die
Status | Terminated |
Enrollment | 50 |
Est. completion date | |
Est. primary completion date | April 2005 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction - Metastatic or unresectable local-regional disease - Osseous metastasis as the only site of disease not eligible - Measurable disease - Mediastinal or hilar lymph nodes must be at least 2.0 cm in diameter by CT scan or MRI to be considered measurable - No known brain metastases - Performance status - Zubrod 0-2 - Performance status - Karnofsky 60-100% - At least 12 weeks - Absolute granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 8 g/dL - Bilirubin no greater than 1.5 mg/dL - SGOT and/or SGPT no greater than 2.0 times upper limit of normal (ULN) - Creatinine no greater than 1.5 times ULN - Creatinine clearance at least 60 mL/min - Calcium no greater than 12 mg/dL - No symptomatic hypercalcemia under treatment - No New York Heart Association class III or IV heart disease - No angina within the past 6 months - No myocardial infarction within the past 6 months - No congestive heart failure within the past 6 months - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No other concurrent active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix - Prior malignancies with no evidence of disease for at least 2 years are allowed - No serious concurrent infection that is uncontrolled or whose control could be jeopardized by complications of study therapy - No concurrent nonmalignant medical illness that is uncontrolled or whose control could be jeopardized by complications of study therapy - No psychiatric disorder or other condition that would preclude study compliance - No prior immunotherapy (including adjuvant or preoperative regimens) - No concurrent biological response modifiers - No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) - No prior chemotherapy (including adjuvant or preoperative regimens and radiosensitizers) - At least 4 weeks since prior radiotherapy and recovered - No prior radiotherapy to major bone marrow containing areas (e.g., pelvis or lumbar spine) or area that contained the indicator lesion - No prior radiotherapy involving 30% or more of the bone marrow - No concurrent radiotherapy - At least 2 weeks since prior major surgery (4 days for minor surgery) and recovered - No other concurrent investigational drugs - No other concurrent antineoplastic therapy |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response (OR) defined as a complete or partial remission, evaluated using RECIST criteria | 8 weeks | No | |
Secondary | Duration of response | From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 6 months | No | |
Secondary | Toxicity graded according to the Common Toxicity Criteria version 2 | Up to 6 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT01249443 -
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
|
Phase 1 | |
Completed |
NCT01612546 -
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
Withdrawn |
NCT02344810 -
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
Terminated |
NCT00064259 -
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00045526 -
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05856500 -
A Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors
|
N/A | |
Completed |
NCT01129206 -
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
|
Phase 2 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Completed |
NCT00607594 -
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
|
Phase 2 | |
Completed |
NCT00397384 -
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
|
Phase 1 | |
Completed |
NCT00077545 -
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
|
Phase 2 | |
Completed |
NCT01231399 -
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00031681 -
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
|
Phase 1 | |
Completed |
NCT00030498 -
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
|
Phase 1 | |
Active, not recruiting |
NCT03154190 -
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
|
N/A | |
Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 |